Bibliography
- Lavanchy D : Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention.J. Clin. Virol.34(Suppl. 1) , S1–S3 (2005).
- Kane A , LloydJ, ZaffranM, SimonsenL, KaneM: Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates.Bull. World Health Organ.77 , 801–807 (1999).
- Heijtink RA , PaulijW, van Roosmalen M et al.: Characteristics of the early phase of chronicity in acute hepatitis B infection. J. Med. Virol.57 , 331–336 (1999).
- Bianco E , StroffoliniT, SpadaE et al.: Case fatality rate of acute viral hepatitis in Italy: 1995–2000. An update. Dig. Liver Dis.35 , 404–408 (2003).
- Wright TL : Introduction to chronic hepatitis B infection.Am. J. Gastroenterol.101(Suppl. 1) , S1–S6 (2006).
- Shouval D : Hepatitis B vaccines.J. Hepatol.39(Suppl. 1) , S70–S76 (2003).
- Assad S , FrancisA: Over a decade of experience with a yeast recombinant hepatitis B vaccine.Vaccine18 , 57–67 (1999).
- Chang MH : Hepatocellular carcinoma in children.Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi39 , 366–370 (1998).
- Clements CJ , BaopingY, CrouchA et al.: Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine24 , 1975–1982 (2006).
- Sjogren MH : Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination.Am. J. Med.118(Suppl. 10A) , 34S–39S (2005).
- Trevisan A , Borella-VenturiniM, Di Marco L: Compliance with hepatitis B virus vaccine: a matter of force? Am. J. Infect. Control34 , 465–466 (2006).
- Macdonald V , DoreGJ, AminJ, van Beek I: Predictors of completion of a hepatitis B vaccination schedule in attendees at a primary health care centre. Sex. Health4 , 27–30 (2007).
- Klinman DM : Adjuvant activity of CpG oligodeoxynucleotides.Int. Rev. Immunol.25 , 135–154 (2006).
- Peng SL : Signaling in B cells via Toll-like receptors.Curr. Opin. Immunol.17 , 230–236 (2005).
- Tighe H , TakabayashiK, SchwartzD et al.: Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol.30 , 1939–1947 (2000).
- Tighe H , TakabayashiK, SchwartzD et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol.106 , 124–134 (2000).
- Marciani DJ : Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.Drug Discov. Today8 , 934–943 (2003).
- HogenEsch H : Mechanisms of stimulation of the immune response by aluminum adjuvants.Vaccine20(Suppl. 3) , S34–S39 (2002).
- Hunter RL : Overview of vaccine adjuvants: present and future.Vaccine20(Suppl. 3) , S7–S12 (2002).
- Data on File: Berkeley, California: Dynavax Technologies Corporation.
- Sewell KL , GearyRS, BakerBF et al.: Phase I trial of ISIS 10.838, a 2´-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J. Pharmacol. Exp. Ther.303 , 1334–1343 (2002).
- Banatvala JE , Van Damme P: Hepatitis B vaccine – do we need boosters? J. Viral Hepat.10 , 1–6 (2003).
- McMahon BJ , BrudenDL, PetersenKM et al.: Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann. Intern. Med.142 , 333–341 (2005).
- Halperin SA , Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ: A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine21 , 2461–2467 (2003).
- Halperin SA , DobsonS, McNeilS et al.: Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine24 , 20–26 (2006).
- Lim SG , ChowWC, ReadingS, Freeman A, Levitt D, Petersen C: Recombinant hepatitis B virus surface antigen (rHBsAg) co-administered with an immunostimulatory phosphorothioate oligonucleotide (1018 ISS) provides superior protection in 40–70 year old subjects. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA, 16–19 December 2005.
- Sablan BP , KimDJ, BarzagaNG et al.: A Phase 3 study comparing vaccination with hepatitis B surface antigen combined with immunostimulatory phosphorotioate oligonucleotide (1018 ISS) to conventional hepatitis B vaccine in older adults. Presented at: European Association for Study of Liver. Barcelona, Spain, 11–15 April 2007.
- Boland G , BeranJ, LievensM et al.: Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine23 , 316–320 (2004).
- Jacques P , MoensG, DesombereI et al.: The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine20 , 3644–3649 (2002).
- Shapira MY , ZeiraE, AdlerR, ShouvalD: Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine.J. Hepatol.34 , 123–127 (2001).
- Rendi-Wagner P , ShouvalD, GentonB et al.: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine24 , 2781–2789 (2006).
- Michel ML , Mancini-BourgineM: Therapeutic vaccination against chronic hepatitis B virus infection.J. Clin. Virol.34(Suppl. 1) , S108–S114 (2005).
- Dix C : PowderMed‘s therapeutic DNA vaccine for chronic hepatitis B enters Phase I clinical trials in patients. In: Press Release: 29th March 2006, Oxford, UK (2006).
- Visvanathan K , LewinSR: Immunopathogenesis: role of innate and adaptive immune responses.Semin. Liver Dis.26 , 104–115 (2006).